Compare AU

Compare CURE vs. WRLD

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Managed Risk Global Share Fund (Managed Fund) (WRLD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

WRLD

Popularity

Low

Low

Pearlers invested

83

3

Median incremental investment

$619.50

$2,002.75

Median investment frequency

Monthly

Quarterly

Median total investment

$1,475.04

$2,718.30

Average age group

> 35

26 - 35


Key Summary

CURE

WRLD

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

WRLD.AX was created on 2015-12-16 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide exposure to a broadly diversified portfolio of global shares, whilereducing the volatility of the equity investment returns and defending against losses in decliningmarkets.

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

APPLE INC (5.30 %)

MICROSOFT CORP (5.02 %)

NVIDIA CORP (4.56 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Other (29.91 %)

Information Technology (23.98 %)

Health Care (8.49 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

United States (71.69 %)

Japan (6.93 %)

United Kingdom of Great Britain and Northern Ireland (3.99 %)

Management fee

0.45 %

0.54 %


Key Summary

CURE

WRLD

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

0.54 %

Price

$52.68

$20.91

Size

$36.301 million

$52.727 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

1.79 %

Market

ASX

ASX

First listed date

12/11/2018

21/12/2015

Purchase fee

$6.50

$6.50


Community Stats

CURE

WRLD

Popularity

Low

Low

Pearlers invested

83

3

Median incremental investment

$619.50

$2,002.75

Median investment frequency

Monthly

Quarterly

Median total investment

$1,475.04

$2,718.30

Average age group

> 35

26 - 35


Pros and Cons

CURE

WRLD

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

WRLD

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home